van Dekken H - Search Results

1

Cure of Barrett's carcinoma by ifosfamide chemotherapy.

Siersema PD, Hage M, van der Gaast A, van Dekken H, Kok TC, Tilanus HW, Kuipers EJ. Siersema PD, et al. Among authors: van dekken h, van der gaast a. Eur J Gastroenterol Hepatol. 2002 Nov;14(11):1261-4. doi: 10.1097/00042737-200211000-00016. Eur J Gastroenterol Hepatol. 2002. PMID: 12439123

2

Cure of Barrett's carcinoma by ifosfamide chemotherapy.

Hage M, van Dekken H, Siersema PD. Hage M, et al. Among authors: van dekken h. Eur J Gastroenterol Hepatol. 2003 Jul;15(7):829. doi: 10.1097/01.meg.0000059139.68845.4f. Eur J Gastroenterol Hepatol. 2003. PMID: 12811316 No abstract available.

3

Molecular evaluation of ablative therapy of Barrett's oesophagus.

Hage M, Siersema PD, Vissers KJ, Steyerberg EW, Haringsma J, Kuipers EJ, van Dekken H. Hage M, et al. Among authors: van dekken h. J Pathol. 2005 Jan;205(1):57-64. doi: 10.1002/path.1685. J Pathol. 2005. PMID: 15586364 Clinical Trial.

4

Genomic analysis of Barrett's esophagus after ablative therapy: persistence of genetic alterations at tumor suppressor loci.

Hage M, Siersema PD, Vissers KJ, Dinjens WN, Steyerberg EW, Haringsma J, Kuipers EJ, van Dekken H. Hage M, et al. Among authors: van dekken h. Int J Cancer. 2006 Jan 1;118(1):155-60. doi: 10.1002/ijc.21302. Int J Cancer. 2006. PMID: 16032707 Free article.

5

Long-term risk of oesophagitis, Barrett's oesophagus and oesophageal cancer in achalasia patients.

Leeuwenburgh I, Haringsma J, Van Dekken H, Scholten P, Siersema PD, Kuipers EJ. Leeuwenburgh I, et al. Among authors: van dekken h. Scand J Gastroenterol Suppl. 2006;(243):7-10. doi: 10.1080/00365520600664201. Scand J Gastroenterol Suppl. 2006. PMID: 16782616 Review.

6

Rising incidence of clinically evident Barrett's oesophagus in The Netherlands: a nation-wide registry of pathology reports.

Post PN, Siersema PD, Van Dekken H. Post PN, et al. Among authors: van dekken h. Scand J Gastroenterol. 2007 Jan;42(1):17-22. doi: 10.1080/00365520600815654. Scand J Gastroenterol. 2007. PMID: 17190757

7

High-grade dysplasia in Barrett's esophagus is associated with increased expression of calgranulin A and B.

Bax DA, Siersema PD, Haringsma J, Kuipers EJ, Vos AJ, Van Dekken H, Van Vliet AH, Kusters JG. Bax DA, et al. Among authors: van vliet ah, van dekken h. Scand J Gastroenterol. 2007 Aug;42(8):902-10. doi: 10.1080/00365520601138189. Scand J Gastroenterol. 2007. PMID: 17613918

8

Aneuploidy and high expression of p53 and Ki67 is associated with neoplastic progression in Barrett esophagus.

Kerkhof M, Steyerberg EW, Kusters JG, van Dekken H, van Vuuren AJ, Kuipers EJ, Siersema PD. Kerkhof M, et al. Among authors: van dekken h, van vuuren aj. Cancer Biomark. 2008;4(1):1-10. doi: 10.3233/cbm-2008-4101. Cancer Biomark. 2008. PMID: 18334729

9

Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.

Sikkema M, Kerkhof M, Steyerberg EW, Kusters JG, van Strien PM, Looman CW, van Dekken H, Siersema PD, Kuipers EJ. Sikkema M, et al. Among authors: van dekken h, van strien pm. Am J Gastroenterol. 2009 Nov;104(11):2673-80. doi: 10.1038/ajg.2009.437. Epub 2009 Jul 28. Am J Gastroenterol. 2009. PMID: 19638963

10

Expression, localization and polymorphisms of the nuclear receptor PXR in Barrett's esophagus and esophageal adenocarcinoma.

van de Winkel A, Menke V, Capello A, Moons LM, Pot RG, van Dekken H, Siersema PD, Kusters JG, van der Laan LJ, Kuipers EJ. van de Winkel A, et al. Among authors: van dekken h, van der laan lj. BMC Gastroenterol. 2011 Oct 6;11:108. doi: 10.1186/1471-230X-11-108. BMC Gastroenterol. 2011. PMID: 21977915 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

173 results

Search Page